Jacob Chacko - Sep 22, 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Stock symbol
ORIC
Transactions as of
Sep 22, 2025
Transactions value $
-$1,349,938
Form type
4
Date filed
9/24/2025, 04:30 PM
Previous filing
Jun 20, 2025
Next filing
Oct 2, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chacko Jacob PRESIDENT AND CEO, Director C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO /s/ Christian Kuhlen, attorney-in-fact 2025-09-24 0001608936

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Sale -$1.35M -125K -16% $10.80 656K Sep 22, 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.
F2 Represents the weighted average share price of an aggregate total of 125,000 shares sold in the price range of $10.57 to $10.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Includes 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F4 The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.